G1 Therapeutics to Participate in Two Investor Conferences in March
G1 Therapeutics (Nasdaq: GTHX) announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
G1 Therapeutics (Nasdaq: GTHX) announced its participation in two upcoming investor conferences. CEO Jack Bailey will present at the HC Wainwright Global Life Sciences Conference starting March 9, 2021, at 7:00 AM ET. He will also engage in a fireside chat at the Roth 33rd Annual Conference on March 17, 2021, at 10:30 AM ET. Both conferences are virtual, and webcasts can be accessed via the company's website.
G1 Therapeutics focuses on developing therapies to improve cancer treatment, including its product COSELA™.
Details
News Market Reaction – GTHX
The recorded move for GTHX in the trading session of this news was -6.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., March 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two investor conferences in March.
Jack Bailey, G1’s Chief Executive Officer, will provide a presentation during the HC Wainwright Global Life Sciences Conference; this presentation will be available starting on March 9, 2021 at 7:00 AM ET. In addition, Mr. Bailey will also participate in a fireside chat during the Roth 33rd Annual Conference on March 17, 2021 at 10:30 AM ET.
These conferences are being held virtually, and webcasts will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.